Logo
Olidia PLLA (Poly L Lactic Acid) Dermal Filler 365 mg

Olidia PLLA (Poly L Lactic Acid) Dermal Filler 365 mg

Olidia

Injectable collagen-stimulating dermal filler (CE-marked medical device)
  • CE Approved injectable poly L Lactic acid dermal filler (Olidia is CE Marked as a sterile absorbable PLLA dermal filler medical device for use in the European market).
  • Approved as a medical device by the Korean Ministry of Food and Drug Safety (MFDS) for indications including facial wrinkles, volume loss and contour deformities.
  • Manufactured by PRP SCIENCE Co., Ltd. in the Republic of Korea in facilities operating under medical device quality systems (the IFU references CE marking and the manufacturer’s details; trade documentation notes ISO 13485 and related quality certifications).
  • Complies with single Use medical device labelling requirements, including symbols for sterile packaging, temperature limitations, non Reuse, and CE marking with notified body identification (as shown in the IFU).
  • Clinical data cited by distributors describe long Term performance with high volume retention and increased collagen deposition (e.g. trial NCT04568902), supporting the biostimulatory efficacy claims of PLLA Based dermal fillers.
  • Olidia uses PLLA, a synthetic, biodegradable polymer that is widely recognised and used in various FDA and MFDS Approved medical devices, such as absorbable sutures and other soft Tissue augmentation products.
Poly-L-lactic acid (PLLA) biodegradable injectable dermal filler for facial wrinkles, folds, volume loss and contour restoration

Description

Olidia PLLA (Poly L-Lactic Acid) Dermal Filler is a sterile, absorbable, injectable poly-L-lactic acid-based dermal filler designed to provide progressive, long-lasting restoration of facial volume and correction of wrinkles and contour defects. Supplied as a dry powder in a single-use vial, it is reconstituted before injection and administered into the deep dermis or subcutaneous tissue. The main ingredient, poly-L-lactic acid (PLLA) powder, stimulates the body’s own collagen production and helps restore its natural structural function, counteracting age-related collagen loss that leads to sagging and loss of firmness. According to the official instructions for use (IFU), Olidia is indicated for treatment of severe facial wrinkles and folds, replacement of volume defects, facial lipoatrophy and improvement of facial contour deformities. Distributor descriptions (including Teleta and other international wholesalers) also highlight its use for hand and neck enhancement and scar refinement. Each vial contains a total of 365 mg of powder (150 mg PLLA, 90 mg sodium carboxymethylcellulose and 125 mg mannitol). Olidia is CE-approved and approved by the Korean MFDS as a sterile absorbable PLLA dermal filler, and is positioned as a long-lasting collagen stimulator with results that can persist for approximately 2–3 years after a structured treatment course.

Bnefits

  • Stimulates endogenous collagen production via poly-L-lactic acid microparticles, helping to restore the skin’s structural framework and firmness over time.
  • Provides gradual, natural-looking correction of facial volume loss, severe wrinkles and contour deformities rather than an immediate, short-lived volumising effect.
  • Indicated in the IFU for treatment of severe facial wrinkles and folds, replacement of volume defects, facial lipoatrophy and improvement of facial contour deformities.
  • Distributor product pages additionally describe benefits for hand and neck enhancement and scar refinement when used by trained professionals.
  • Long-lasting results: trade and clinical summaries report durable improvements that can last around 2–3 years after 3–4 treatment sessions, depending on patient factors and protocol.
  • Biodegradable and biocompatible PLLA composition derived from a synthetic polymer with more than 20 years of use in medical devices such as absorbable sutures.
  • CE-marked in Europe and approved by the Korean MFDS as a sterile absorbable PLLA dermal filler, supporting recognized safety and performance standards as a medical device.
  • Formulation includes carboxymethylcellulose and mannitol to support reconstitution, particle dispersion and handling characteristics.
  • Can address a broad range of aesthetic indications including nasolabial folds, marionette lines, midface volume loss, jawline and chin contouring when injected appropriately.
  • Offers an alternative to hyaluronic-acid-based dermal fillers for patients seeking a more gradual, collagen-driven rejuvenation with extended longevity.

Indications

  • According to the official Olidia IFU: treatment of severe facial wrinkles and folds.
  • Replacement of volume defects in the face as stated in the IFU.
  • Facial lipoatrophy treatment as listed in the IFU indications.
  • Improvement of facial contour deformities according to the IFU.
  • Teleta and other distributor listings additionally cite: treatment of facial wrinkles and folds, filling lost volume, facial lipoatrophy, facial contour deformities, hand and neck enhancement and scar refinement.
  • Intended use in the IFU: injection using a syringe into the deep dermis for the above aesthetic indications in adults, performed only by appropriately trained specialist doctors.

Composition

  • Each vial of dry powder contains, according to the Olidia IFU:
  • – 150 mg of Poly-L-lactic acid (PLLA).
  • – 90 mg of Sodium Carboxymethylcellulose.
  • – 125 mg of Mannitol.
  • Total powder content per vial: 365 mg (PLLA + sodium carboxymethylcellulose + mannitol).
  • No animal- or human-derived proteins are listed in the IFU; PLLA is a fully synthetic, biodegradable polymer.
  • The IFU specifies that the product is a sterile, absorbable poly-L-lactic acid dermal filler intended to be reconstituted with sterile water for injection before use.

Formulation

  • Pharmaceutical / device form: sterile absorbable poly-L-lactic acid dermal filler supplied as a lyophilised powder in a single-use glass vial.
  • Actives and excipients per vial (dry powder): 150 mg PLLA, 90 mg sodium carboxymethylcellulose, 125 mg mannitol (total 365 mg).
  • Upon reconstitution with sterile water for injection (5 ml WFI per IFU), Olidia forms a uniform translucent suspension for injection into the deep dermis or hypodermis.
  • The carboxymethylcellulose and mannitol components assist with suspension stability and particle dispersion (PSPCM-type formulation).
  • Mechanism of action: PLLA microparticles act as a biostimulatory scaffold that induces fibroblasts to produce new collagen, leading to progressive restoration of volume, improved skin elasticity and smoothing of wrinkles.
  • Biodegradation: PLLA is gradually broken down by hydrolysis and metabolised to carbon dioxide and water over time; as the particles resorb, the newly formed collagen matrix remains, providing long-term volume.
  • Device classification: CE-marked sterile injectable PLLA dermal filler and MFDS-approved medical device; specific EU risk class and notified-body number are referenced in the IFU via the CE mark but not fully detailed in public summaries.

Packaging

  • Primary container: single-use glass vial containing 365 mg of sterile dry powder (150 mg PLLA, 90 mg sodium carboxymethylcellulose, 125 mg mannitol).
  • Closure system: rubber stopper and aluminium cap as described in the IFU; the rubber stopper must be disinfected with antiseptic before piercing.
  • Secondary packaging: one vial per box ("Contains 1x365mg (1×5.0ml)" as stated on Teleta’s product page).
  • Labelling (from IFU and trade listings): product name (Sterile Absorbable Poly-L-Lactic Acid Dermal Filler), brand name Olidia, composition per vial, manufacturer (PRP SCIENCE Co., Ltd., Republic of Korea), CE mark, and MFDS-related details.
  • Pack is supplied sterile and designated for single-patient, single-use only; reuse or resterilisation is prohibited by the IFU.

Usage

  • Professional use only: Olidia must be used exclusively by specialist doctors or appropriately trained healthcare professionals who have completed mandatory training in PLLA injection techniques, as specified in the IFU.
  • Preparation before use (per IFU):
  • 1. Check that the product packaging is intact and undamaged; do not use if the sealed package, aluminium cap or rubber stopper is damaged.
  • 2. Inspect the vial for any deformation or foreign material.
  • 3. Remove the cap and wipe the rubber stopper with an antiseptic.
  • Reconstitution (per IFU for Olidia 365 mg vial):
  • 4. Connect an 18G sterile needle to a 5 ml sterile single-use syringe.
  • 5. Slowly add 5 ml of sterile Water for Injection (WFI) into the vial through the rubber stopper.
  • 6. Allow the vial to stand for at least 3 hours to ensure complete hydration; do not shake during this hydration period.
  • 7. Immediately before use, gently agitate the vial until a uniform translucent suspension is obtained; a vial swirling agitator may be used.
  • 8. The reconstituted product must be used within 72 hours; if not used within 72 hours it must be discarded.
  • Withdrawal and injection technique (per IFU):
  • 9. Before each withdrawal, wipe the rubber stopper with antiseptic.
  • 10. Use an 18G sterile needle attached to a 1 or 3 ml sterile syringe to withdraw the required volume of suspension.
  • 11. For injection, use a sterile 26G needle or 26G blunt cannula depending on the treatment plan.
  • 12. Injection is performed into the lower layers of the dermis or hypodermis using linear threading or similar techniques; the IFU emphasises injection into deep dermis rather than superficial placement to reduce the risk of papules or nodules.
  • 13. During injection, periodically massage the injection site to distribute the product evenly and help achieve a smooth correction.
  • Distributor / clinic dilution protocol (from Teleta and other trade sources – used in clinical practice but not replacing the IFU):
  • – Prepare 9 ml of diluted Olidia solution as follows: 1 vial (5 ml reconstituted Olidia suspension) + 7 ml saline + 2 ml lidocaine, yielding three 3 ml syringes (3 ml × 3).
  • – This dilution scheme is described on Teleta and other distributor sites for practical use; injectors must adapt to local regulations and patient needs and remain within the framework of the official IFU.
  • Patient information and aftercare (per IFU and PLLA practice):
  • 14. Inform patients that swelling immediately after injection may temporarily make the area appear fully corrected; this swelling usually resolves within hours to a few days, and original contour deficiencies may reappear before collagen stimulation leads to longer-term improvement.
  • 15. Patients are typically instructed to massage the treated area for 5 minutes, 5 times a day (the IFU describes massage to promote natural-looking correction) for several days after each treatment, according to practitioner guidance.
  • 16. Explain that multiple treatment sessions may be needed to achieve optimal results and that overcorrection in a single session should be avoided.
  • 17. As with all transdermal injections, strict aseptic technique must be used and injection into blood vessels must be avoided; aspiration and careful technique are recommended to minimise vascular risk.

Contraindications

  • As listed in the official Olidia IFU:
  • – Do not inject Olidia in patients with acute or chronic skin diseases (infection or inflammation) at the injection site or surrounding areas.
  • – Do not use in patients who are highly sensitive to the product or any of its components (PLLA, sodium carboxymethylcellulose, mannitol).
  • – The safety of using Olidia in patients susceptible to excessive scarring (e.g. keloids) has not been established; such patients are contraindicated in the IFU.
  • – Use in patients with a history of herpetic eruptions may lead to recurrence of herpetiform lesions.
  • – Do not inject in patients with liver dysfunction or blood coagulation disorders.
  • Additional IFU cautions and limitations:
  • – Safety and effectiveness have not been established in pregnant or breastfeeding women or in patients under 18 years of age.
  • – The IFU states that the safety and effectiveness for lip augmentation and some off-label areas have not been established.
  • – Do not inject into blood vessels; intravascular injection can lead to serious adverse events including embolism and potential loss of vision.
  • – Treatment should not be performed in the presence of active inflammation or infection at the intended injection site until resolved.

Adverse Effects

  • Potential adverse events listed in the Olidia IFU include injection-site reactions such as haemorrhage, pain, induration, swelling, tenderness, lesions, bleeding and fever.
  • Immune system-related reactions noted in the IFU include hypersensitivity and angioedema, skin sarcoidosis, dermatitis and severe allergic reactions (including palpitations, urticaria, keloids and systemic autoimmune-type responses).
  • The IFU highlights the possibility of papules or nodules at the injection site, particularly if the product is placed too superficially or not evenly distributed.
  • Like other injectable fillers, there is a risk of infection at the injection site; standard aseptic technique and appropriate patient screening are essential.
  • Serious adverse events from intravascular injection can include embolic events and tissue ischaemia; the IFU warns specifically that injection into blood vessels may cause obstruction and serious complications.
  • Post-marketing and clinic reports for PLLA fillers in general also describe transient redness, bruising and tenderness, which typically resolve within days; long-term safety data beyond the established study periods are noted in the IFU as not fully evaluated.

Storage Conditions

  • The IFU specifies that Olidia is susceptible to high temperatures and should not be stored above 30°C.
  • Do not refrigerate or freeze Olidia; storage in environments over 30°C or in a refrigerator/freezer is prohibited.
  • Protect vials from strong impact or collision to avoid damage.
  • Olidia is supplied sterile and is intended for single use only; it must not be reused or resterilised once the sealed package is opened or the product has been reconstituted.
  • Any unused reconstituted suspension not injected within 72 hours of reconstitution must be discarded.
  • Dispose of used vials and sharps as medical waste according to local regulations and in designated collection containers.
  • Keep out of the reach of children and store in the original packaging until use.

Duration

According to distributor summaries and clinical marketing data, Olidia PLLA is typically administered as a series of approximately 3\u20134 treatment sessions spaced about 4\u20136 weeks apart, with progressive improvement over several months. The IFU notes that effects gradually appear within several weeks after injection and advises against overcorrection. Trade sources referencing clinical data (e.g. NCT04568902) report maintenance of a high proportion of volume improvement up to 25 months and overall aesthetic effects lasting around 2\u20133 years after a completed course, though exact duration and retreatment intervals are determined by the treating physician based on the IFU and individual patient response.

Onset

The IFU and trade summaries explain that an initial apparent correction due to injection volume and transient swelling may be visible immediately after treatment but often subsides within hours to a few days, with the original defect reappearing. True corrective effects from collagen stimulation develop gradually over several weeks, with noticeable improvement typically emerging from about 4\u20138 weeks after injection and continuing to build over subsequent months.

Browse more Injectable collagen-stimulating dermal filler (CE-marked medical device)

Top Treatments

Top Cities in the UK